SynthesisJAMA network open2020

Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis.

Seema Gulia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.